Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)

Contributed by: Business Wire

Tags

Biotechnology
Mental Health
Health
Pharmaceutical
Clinical Trials
HMNC Brain Health

More Like This

Ketabon To Present Advancements In At-Home Ketamine Therapy For Treatment-Resistant Depression At American Society Of Clinical Psychopharmacology Annual Meeting

Head-to-head Trial of Prolonged-Release Oral Ketamine Formulation, KET01, and Intranasal SPRAVATO®, Finds Less Incidence of Dissociation or Cardiovascular Effects with Oral Treatment, at doses used for Treatment-Resistant Depression

Strong and durable effects 4 months after 2 doses (Graphic: Business Wire)

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Business Wire logo

MindMed Announces Business Update and Anticipated Milestones for 2024

Business Wire logo

TauRx Submits UK Marketing Authorisation Application for HMTM as a Treatment for Alzheimer’s Disease

Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA

Ketabon To Present Advancements In At-Home Ketamine Therapy For Treatment-Resistant Depression At ECNP Congress 2024

Denovo Biopharma Announces a Major Breakthrough in Treatment‑Resistant Depression with Precision Medicine